MRK Merck & Co Inc

$MRK $MRNA $BCTX Yes and that’s why a tiny micro micro cap with a platform that has a higher efficacy with minimal side effects, off shelf yet personalized at a fraction of the cost. This will be the true world wide public health miracle for cancer. Fantasy ? We will know in a couple of months when the phase 3 breast cancer trial reports interim results. Moderna’s vaccine a miracle which will be a commercial failure due to the 8 week delay, outrageous cost which insurance companies will not pay. Limited to certain subset.

$MRK Very unusual trade 1.5M 130P 100% at the ask, buy. For JAN EXP I'm taking a lotto piggy backing this whale into these 2.70 AVG Under his 2.80 AVG Something smells 'insider' about this, as if the person knowns bad news/event is on the way This is being treated as a whale lotto trade

$MRK When I saw this order flow whale pre-leak we should have done $MRNA puts instead Fumbled the bag and followed into the MRK PUTS instead of MRNA which moved 700% This whale clearly had inside info on the data days before. I posted this whale flow alert on Oct 20

$MRK Added more here 2.69 avg Something is up with this print into a big catalyst like Sat Pure lotto but could pay 500-1000% if plays out

$MRK $RVMD $SLS 🤯 GPS Next up. 1. E mail from Sellas with just ASH 2026 Event presentation without Actual material because Data is under ASH 2026 Embargo. 2. QP start perfectly aligns with preparation for ASH 2026 Submission. 3. E mail from John F. QP related to Regal Phase 3 only. 4. Dr. Stergiou post Next best Chaper coming. 👇 ✌️🙏❤️‍🩹

Mid-week Chat conversations: Stunning data for $MRK's tulisokibart in hidradenitis suppurativa (whole new market opened up for TL1A) Good for peers like $SYRE $XNCR with "me-betters", bearish for other contenders like $MLTX $IOVA multi-bagger for a few ppl, NSCLC update soon

$MRK so much for the breakout. News drop. Results with $MRNA wasnt as food as expected. Stopped out at a loss

$MRK Just the thought of it, an inch away from walking away from Keytruda. $SMMT challenges that history? HARMONi-2 goes Head-to-Head vs. Keytruda Monotherap, median OS 30 vs 22 $CMPX following smmt's foot path to regulatory hurdle

$MRK Dumping hard. Owning JAN puts for this to retrace. Whale bought 130 strike and so did I

$MRK BULLFLAG forming on daily right below it's all time highs trendline resistance on daily time frame, $150 break & close on watch for an explosive move out of this flag to $153/$157/$160+ Support: $147/$146

$MRK $MRNA $SLS Exactly! Look at how the market rewards platform validation: • The Phase 2 Proof: Moderna added $20 Billion in value when they first dropped their mid-stage cancer vaccine data. • The Phase 3 Launch: Moderna is absolutely bursting through multi-year highs—adding over $60 Billion in market value since announcing its pivotal Phase 3 results for skin cancer in August. And Moderna achieved that massive enterprise re-rating for a hyper-customized, slow, and expensive platform. We hold the keys to an off-the-shelf, cost-efficient, fridge-ready dual-engine monopoly (GPS + SLS009) right at the final finish line. The REGAL math is locked. The launch sequence is primed. Know what you hold. 💎🙌🔓

$MRK Price: $145.27 Volume: Average or below Catalyst: Ongoing Keytruda pipeline updates and patent-cliff concerns continue to drive sentiment. Resistance: $149.50 Support: $142.00 Bull case: Reclaiming $149.50 on rising volume opens the door back toward the mid-$150s. Bear case: A breakdown below $142.00 support signals further downside toward the high $130s. What I'm watching: Need volume to confirm any move through either level before trusting the breakout or breakdown. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $MRK |

Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’ $MRK $MRNA $XBI https://stocktwits.com/news/equity/markets/merck-ceo-plays-down-cost-concerns-over-intismeran-we-don-t-see-cost-as-a-limit-to-access/cZxyldnRBxs

$MRK $JNJ Defensive large caps get tradeable dips too. Both pulled back inside uptrends in early Oct: $MRK in at 139.56 and $JNJ at 252.93 on Oct 5, both out two days later, up about 2.5% each. Nothing dramatic. Small, repeatable pops on strong names, sold into the bounce.

$MRK Merck-Moderna melanoma add-on cut recurrence or death risk 42% in Phase 3, not in first 6 months. 🏢 Merck, maker of cancer drug Keytruda, is worth about $366.92B at $148.72 a share, 15:19 ET Oct 22, 2026 📈 After six months of no difference (HR 0.99) during intismeran dosing, risk fell 58% vs Keytruda alone (HR 0.42) in a pre-specified sensitivity analysis ⚠️ Overall survival data are not yet mature, though a favorable trend has been observed and the study continues 📅 Next: Merck Oncology Investor Event at ESMO, Monday, Oct. 26, 2026, 1 p.m. EDT Source: Business Wire release, Oct 22 + SEC 8-K, Aug 4

Shares of Merck, a much larger drugmaker, fell by about 1% on Thursday. The company’s stock has climbed nearly 41% this year. Since the vaccine is personalized, the complicated manufacturing process can take six weeks. But Merck CEO Robert Davis told CNBC last week that the company believes it can shorten that timeline in the future, potentially allowing the shot to reach more patients more quickly. $MRK

$MRK was all but dead last year! It’s done quite well ever since the Talking Heads were yelling “ sell sell sell!”

$MRK VMS Asset Management initiated a $5.39 million Merck stake by purchasing 37,095 shares in the third quarter, making Merck about 2.1% of its portfolio. Institutional investors collectively own 76.07% of the company.

$MRK FDA accepted for review the first publicly announced Keytruda biosimilar application, Formycon and Zydus's FYB206 (companies' release today). Keytruda did 31.6 billion dollars for Merck in 2025, almost half the company's total sales. FYB206 was developed without a comparative Phase III efficacy trial, on a pathway agreed with FDA in early 2025. A decision is expected in Q3 2027 under the 12-month BsUFA clock. Acceptance is not approval, and patent questions still sit between here and any launch. The clock on biosimilar competition for Merck's biggest drug is now actually running.